Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need...

[cafead]

via With the ink still drying on Arrowhead Pharmaceuticals’ recent announcement of successful 48-week results in a phase 2 trial of its RNAi drug candidate plozasiran, analysts are already projecting much longer-term success for the drug.

article source